- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06096740
Effets de la psychothérapie sur le traitement des récompenses dans le SSPT (PERPP)
Les effets de la psychothérapie axée sur les traumatismes sur la fonction des circuits de récompense et l'encodage des informations
The purpose of this study is to identify how trauma-focused psychotherapy changes the function of brain circuitry in posttraumatic stress disorder (PTSD) and how this mediates improvements in the diminished ability to experience positive emotions following a traumatic or extremely stressful life event. In this instance, the investigators will be using cognitive processing therapy (CPT), a widely-utilized and evidence-based treatment for PTSD.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The goals of the study are as follows:
- Quantify, under conditions of safety (no threat), how PTSD psychotherapy alters reward circuit function and information encoding.
- Identify how presence of threat augments PTSD psychotherapy effects on reward circuit function and information encoding.
- (Exploratory). Identify how, following psychotherapy, changes in reward circuit function and information encoding under conditions of safety and threat are associated with improvements in symptoms of diminished positive affect (DimPA).
To accomplish the goals of the study, the investigators propose a neuroimaging-coupled, randomized clinical trial of immediate vs. delayed individual cognitive processing therapy (CPT) in individuals (N=120) with a primary diagnosis of chronic PTSD. Individuals will undergo, prior to randomization, clinical and neurobiological assessment with functional magnetic resonance imaging (fMRI) during completion of several reward processing paradigms. Two of these involve both a normal "safe" context and a threat context manipulation (threat of mild electrodermal shock that is periodically cycled throughout the task). Another paradigm involves making decisions to either approach reward or forego a reward when this decision conflicts with the likelihood of an aversive outcome. This is known as approach-avoidance conflict (AAC). This battery will provide a comprehensive characterization of reward processing behavior and circuit function and establish its relationship to treatment processes, as well as how such processes may vary as a function of threat.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Lauren Enten, B.S.A
- Numéro de téléphone: 512-495-5856
- E-mail: fonzolab@austin.utexas.edu
Lieux d'étude
-
-
Texas
-
Austin, Texas, États-Unis, 78712
- Recrutement
- Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600
-
Contact:
- Lauren Enten, B.S.A.
- Numéro de téléphone: 512-495-5856
- E-mail: fonzolab@austin.utexas.edu
-
Chercheur principal:
- Greg Fonzo, Ph.D.
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- English as primary language, and comprehension suitable to understand experimenter instructions.
- Current and chronic syndromic PTSD, defined as being exposed to a DSM-5 Criterion A traumatic event, with the presence DSM-5 qualifying PTSD symptoms for at least 3 months, as assessed by the Clinician-Administered PTSD Scale for DSM-5.
- Able and willing to undergo functional magnetic resonance imaging (fMRI).
- Willingness to participate in repeated assessments and as part of a delayed treatment group.
Exclusion Criteria:
- Evidence of current or prior history of psychosis or bipolar disorder as evidenced by self-report or clinical interview.
- Active substance dependence within the past 6 months as evidenced by clinical interview.
- Current regular psychiatric medication use (i.e. antidepressants), except for as-needed benzodiazepine or opiate medication no more than three times per week, on average, or for short-duration stimulant medication for attention deficit hyperactivity disorder that can be skipped within 24 hours of study visits.
- A recent (<6 months) suicide attempt or current active ideation with intent.
- Unremovable ferrous metal in body.
- History of neurological disorder, stroke, seizures/convulsions (except febrile seizures in childhood), epilepsy, brain surgery, electroconvulsive or radiation treatment, brain hemorrhage or tumor, or thyroid disorder.
- Anyone who is pregnant or trying to become pregnant.
- Current or past year (> 3 sessions), psychotherapy with a prominent exposure or cognitive restructuring component.
- Previous or current (es)ketamine treatment and/ or brain stimulation/neuromodulation treatment.
- Other ongoing treatment that is likely to confound experimental effects.
- Previous penetrating head injury/traumatic brain injury. Mild-to-moderate traumatic brain injury without penetrating injury is allowable.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Immediate Treatment
Those individuals randomized to immediate treatment will commence individual cognitive processing therapy (CPT) with an assigned study therapist, following the completion of baseline procedures. |
Cognitive processing therapy is a widely-utilized, empirically-supported treatment developed for PTSD. It is based on a cognitive theory of trauma which emphasizes the impact of trauma on belief systems and the development of "stuck points", which are unhealthy, unrealistic, and maladaptive ways of thinking that serve to maintain unhealthy beliefs and reinforce PTSD symptoms.
Autres noms:
|
|
Comparateur placebo: Delayed Treatment
Individuals randomized to the delayed treatment condition will be informed after randomization that their treatment will start in 6-8 weeks (the approximate period it will take for individuals in the immediate treatment arm to complete CPT and post-treatment assessments). |
Cognitive processing therapy is a widely-utilized, empirically-supported treatment developed for PTSD. It is based on a cognitive theory of trauma which emphasizes the impact of trauma on belief systems and the development of "stuck points", which are unhealthy, unrealistic, and maladaptive ways of thinking that serve to maintain unhealthy beliefs and reinforce PTSD symptoms.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Within subject beta coefficients for each parametrically modulated regressor of the Reinforcement Learning Task with Threat
Délai: [10 weeks]
|
The changes in deoxyhemoglobin driven by localized changes in brain blood flow and blood oxygenation associated with individual trial-by-trial reinforcement learning computational model parameters at the time of choice valuation (expected reward value during safe contexts and expected reward value during threat contexts) and choice outcome (reward prediction errors during safe contexts and reward prediction errors during threat contexts). |
[10 weeks]
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Within-subject BOLD contrast for unexpected absence of juice vs. expected absence of juice (negative temporal Prediction Errors) for safe and threat contexts.
Délai: [10 weeks]
|
The changes in deoxyhemoglobin driven by localized changes in brain blood flow and blood oxygenation between the unexpected absence of juice vs. expected absence of juice in safe contexts and threat contexts. |
[10 weeks]
|
|
Within-subject BOLD contrast for the unexpected delivery of juice vs. the expected delivery of juice (positive temporal Prediction Errors) for safe and threat contexts.
Délai: [10 weeks]
|
The changes in deoxyhemoglobin driven by localized changes in brain blood flow and blood oxygenation between the unexpected delivery of juice vs. the expected delivery of juice in both safe and threat contexts. |
[10 weeks]
|
|
Within subject beta coefficients for each parametrically modulated regressor of an approach avoidance conflict task.
Délai: [10 weeks]
|
The changes in deoxyhemoglobin driven by localized changes in brain blood flow and blood oxygenation associated with individual trial-by-trial reinforcement learning computational model parameters at the time of choice valuation (expected reward value, expected threat value, and conflict between reward and threat value), anticipation (expected reward and threat value), and choice outcome (reward and threat prediction errors). |
[10 weeks]
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in total score of the Clinician Administered PTSD Scale for DSM-5 from baseline to 10 weeks
Délai: 10 weeks
|
A structured clinical interview measure of PTSD symptom severity |
10 weeks
|
|
Change in total score of the PTSD Checklist for DSM-5 from baseline to 10 weeks
Délai: 10 weeks
|
A self-report measure of PTSD symptom severity |
10 weeks
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Gregory A Fonzo, PhD, The University of Texas at Austin
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Troubles liés aux traumatismes et aux facteurs de stress
- Manifestations neurologiques
- Maladies du système nerveux
- Les troubles mentaux
- Manifestations neurocomportementales
- Troubles de stress, traumatiques
- Conditions pathologiques, signes et symptômes
- Signes et symptômes
- Troubles de stress, post-traumatique
- Anhédonie
- 2-cyclohexylidenhydrazo-4-phényl-thiazole
Autres numéros d'identification d'étude
- STUDY00004746
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .